shortagewatch

Home / Carboplatin / Italy

IT ATC L01XA02 · updated 2 Nov 2026

Carboplatin shortage in Italy

Is there a Carboplatin shortage in Italy?

Yes. As of 2 Nov 2026, 11 Carboplatin products are reported short in Italy, the first since 20 Mar 2024. The company estimate for the return is 31 Dec 2026 (latest 31 Mar 2027). Main reason: manufacturing problem.

Also short in United States, Canada, Germany, Spain, Belgium, Switzerland, Czechia, Sweden, Japan. All countries.

Affected products in Italy

CountryProductCompanySinceExpected backReason
ITCARBOPLATINO AHCL discontinuationACCORD HEALTHCARE BV20 Mar 2024not givenManufacturing problem
Problemi produttivi: forniture discontinue
ITCARBOPLATINO TEVATEVA PHARMA B.V.1 Jul 2025not givenManufacturing problem
Problemi produttivi
ITCARBOPLATINO MEDACMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH10 Jul 2025not givenCommercial decision or withdrawal
Motivi commerciali
ITCARBOPLATINO MEDACMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH10 Jul 2025not givenCommercial decision or withdrawal
Motivi commerciali
ITCARBOPLATINO PFIZER discontinuationPFIZER ITALIA S.R.L.31 Jul 2025not givenManufacturing problem
Problemi produttivi
ITCARBOPLATINO AUROBINDO ITALIA discontinuationEugia Pharma (Malta) Limited7 May 2026not givenManufacturing problem
Problemi produttivi
ITCARBOPLATINO PFIZERPFIZER ITALIA S.R.L.1 Jul 202631 Dec 2026Increased demand
Elevata richiesta
ITCARBOPLATINO MEDAC discontinuationMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH5 Aug 2026not givenIncreased demand
Elevata richiesta
ITCARBOPLATINO PFIZERPFIZER ITALIA S.R.L.1 Sep 202631 Mar 2027Manufacturing problem
Problemi produttivi
ITCARBOPLATINO MEDACMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH19 Oct 2026not givenIncreased demand
Elevata richiesta: distribuzione contingentata
ITCARBOPLATINO MEDACMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH19 Oct 2026not givenIncreased demand
Elevata richiesta: distribuzione contingentata

Source

AIFA (Italian Medicines Agency), licensed CC-BY 4.0. Official list. All shortages reported by marketing-authorisation holders, including medicines being withdrawn.